Study on novel treatment techniques for neurogenic gastrointestinal disorders utilizing the neuroendocrine axis and artificial intelligence technology
Not Applicable
- Conditions
- Preventing psychological illness in patients with neurogastroenteropathyNervous System Diseases
- Registration Number
- ISRCTN11239735
- Lead Sponsor
- Chifeng Cancer Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Free from genetic diseases
2. Patients with neural digestive disease, with no mental illness
3. Patients with IBS-D
Exclusion Criteria
Diseases with obvious abnormalities in the auditory system
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain and related symptoms in irritable bowel syndrome (IBS) measured using the IBS-Symptom Severity Scale (IBS-SSS) from baseline monthly up to 6 months
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures